

DAFTAR PUSTAKA

1. Baur X, Sigsgaard T, Aasen TB, Burge PS, Heederik D, Henneberger P, *et al.* Guidelines for the management of work-related asthma. *Eur Respir J.* 2012;39(3):529–45.
2. Peragallo JH. Pediatric Myasthenia Gravis. *Semin Pediatr Neurol.* 2017;24(2):116–21.
3. VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical characteristics of pediatric myasthenia: A surveillance study. *Pediatrics.* 2013;132(4):939–44.
4. Harkitasari S. Diagnosis dan terapi miastenia gravis pada anak. *Cermin Dunia Kedokt.* 2015;42(3):181–5.
5. Vecchio D, Ramdas S, Munot P, Pitt M, Beeson D, Knight R, *et al.* Paediatric myasthenia gravis: Prognostic factors for drug free remission. *Neuromuscul Disord.* 2020;30(2):120–7.
6. Alhaidar MK, Abumurad S, Soliven B, Rezanika K. Current treatment of myasthenia gravis. *J Clin Med.* 2022;11(8):1587–97.
7. Godoy DA, de Mello LJV, Masotti L, Di Napoli M. The myasthenic patient in crisis: An update of the management in Neurointensive care unit. *Arq Neuropsiquiatr.* 2013;71(9 A):627–39.
8. Vanikieti K, Lowwongngam K, Padungkiatsagul T, Visudtibhan A, Poonyathalang A. Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort. *Pediatr Neurol.* 2018;87:36–41.
9. Dresser L, Wlodarski R, Rezanika K, Soliven B. Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations. *J Clin Med.* 2021;10(11):2235.
10. Richman DP. The Future of Research in Myasthenia. *JAMA Neurol.* 2015;13(1):76–9.
11. Finnis MF, Jayawant S. Juvenile myasthenia gravis: A paediatric perspective. *Autoimmune Dis.* 2011;1(1):101–4.
12. Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis. *Autoimmunity.* 2015;48(6):362–8.
13. Verschuuren JJGM, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, *et al.* Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. *Autoimmun Rev.* 2013;12(9):918–23.
14. Heiden JA Vander, Stathopoulos P, Zhou JQ, Chen L, Tamara J, Bolen CR, *et al.* Patients Revealed Through Deep Sequencing. 2018;198(4):1460–73.
15. Arie A, Adnyana M, Widyadharma I. Diagnosis dan Tata Laksana Miastenia Gravis. *Cermin Dunia Kedokt.* 2013;4(2):1–23.
16. Takaba H, Takayanagi H. The Mechanisms of T Cell Selection in the Thymus. *Trends Immunol.* 2017;38(11):805–16.
17. Witthayaweerasak J. Prognostic factors for conversion to generalization in ocular myasthenia gravis. *J Med.* 2021;100(19):e25899.
18. Sen J, Kamath GG, Clearkin LG. Surgically induced diffuse scleritis:

- comparison of incidence in phacoemulsification and conventional extracapsular cataract extraction. *Br J Ophthalmol*. 2002;86(6):701–7.
19. Blaes F. Diagnosis of myasthenia gravis. *J Clin Med*. 2021;10(8).
 20. Witoonpanich R, Dejthevaporn C, Sriphrapradang A, Pulkes T. Electrophysiological and immunological study in myasthenia gravis: Diagnostic sensitivity and correlation. *Clin Neurophysiol*. 2011;122(9):1873–7.
 21. Gadiant P, Bolton J, Puri V. Juvenile myasthenia gravis: Three case reports and a literature review. *J Child Neurol*. 2009;24(5):584–90.
 22. Maggi L, Mantegazza R. Treatment of myasthenia gravis: Focus on pyridostigmine. *Clin Drug Investig*. 2011;31(10):691–701.
 23. Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis. *J Clin Neurol*. 2011;7(4):173–83.
 24. Cs L, Mn UK, Mlc B. Case series of children with steroid-Induced glaucoma. 2018;13(3):32–7.
 25. Nuyen B, Weinreb RN, Robbins SL. Steroid-induced glaucoma in the pediatric population. *J AAPOS*. 2017;21(1):1–6.
 26. Zinman L, Bril V. IVIG treatment for myasthenia gravis: Effectiveness, limitations, and novel therapeutic strategies. *Ann N Y Acad Sci*. 2008;1132:264–70.
 27. Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. *Pediatr Neurol*. 2000;22(1):40–3.
 28. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. *Br J Haematol*. 2014;164(3):342–51.
 29. Mangunatmadja I, Himawan S, Noorshintaningsih D. Perbandingan Plasmaferesis dan Imunoglobulin untuk Terapi Miastenia Gravis Juvenil. *Sari Pediatr*. 2020;21(6):386–93.
 30. Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients. *Muscle and Nerve*. 2010;41(5):593–8.
 31. O’Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. *Front Neurol*. 2020;11(July):1–12.
 32. Smith S V., Lee AG. Update on Ocular Myasthenia Gravis. *Neurol Clin*. 2017;35(1):115–23.
 33. Krueger J. Prognosis in Pediatric Myasthenia Gravis. *Pediatr Neurol Briefs*. 2020;34:24.
 34. Mullins LL, Carpentier MY, Paul RH, Sanders DB, McDermott M, Thornton C, *et al*. Disease-specific measure of quality of life for myasthenia gravis. *Muscle and Nerve*. 2008;38(2):947–56.
 35. Yang Y, Zhang M, Guo J, Ma S, Fan L, Wang X, *et al*. Quality of life in 188 patients with myasthenia gravis in China. *Int J Neurosci*. 2016;126(5):455–62.
 36. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. *BMJ*. 2013;345(7891):1–4.
 37. CADTH. Clinical Review Report Galcanezumab. In 2021. hal. 1–78.

38. Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. *BMC Neurol.* 2017;17(1):1–6.
39. Su JJ, Chiu MJ, Chang YC. Coexistence of Epilepsy and Myasthenia Gravis: Report of Four Patients and Review of the Literature. *Acta Neurol Taiwan.* 2003;12(4):181–6.
40. Sansone G, Bonifati DM. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. *J Neurol.* 2022;269(8):3965–81.
41. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, *et al.* International Consensus Guidance for Management of Myasthenia Gravis. *Neurol.* 2021;96(3):114–22.
42. Suppiah PD, Marshall DS, Lee SM, Looi I. Quality of life and activities of daily living of myasthenia gravis patients in Hospital Seberang Jaya, Malaysia using MGQOL-15 and MGADL scores: A cross sectional study. *Neurol Asia.* 2022;27(1):125–30.
43. De Meel RHP, Raadsheer WF, Van Zwet EW, Tannemaat MR, Verschuuren JJGM. Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature. *J Neuromuscul Dis.* 2019;6(3):369–76.
44. Yu EA, Huey SL, Peña-Rosas JP, Mehta S. The effects of oral vitamin D supplementation on linear growth and non-communicable diseases among infants and children younger than five years of age. *Cochrane Database Syst Rev.* 2017;2017(11).
45. Niken P, Yati P, Rizal J, Batubara L, Wayan I, Suryawan B. Vitamin D. In: *Panduan Praktik Klinis Ikatan Dokter Anak Indonesia.* 2018.
46. Pela I. How much vitamin D for children? *Clin Cases Miner Bone Metab.* 2012;9(2):112–7.
47. Ikatan Dokter Anak Indonesia. Perawakan Pendek pada Anak dan Remaja di Indonesia. *Panduan Praktik Klinis Ikatan Dokter Anak Indonesia.* 2017. hal 1–19.
48. WHO. Guidelines on mental health promotive and preventive interventions for adolescents. World Health Organization. 2020. 1–120.
49. Asyanti S. Dinamika Permasalahan Orangtua yang Memiliki Anak dengan Penyakit Kronis dan Tantangannya dalam Mengantarkan Anak Menjadi Pribadi yang Lebih Sehat dan Tangguh. *J Kesehat Masy.* 2008;49(2):69–73.
50. Ali SH, Foster T, Hall NL. The relationship between infectious diseases and housing maintenance in indigenous Australian households. *Int J Environ Res Public Health.* 2018;15(12).
51. Mishra S. Juvenile Myasthenia Gravis: A Short Review. *Progress Asp Pediatr Neonatol.* 2018;2(1):106–9.
52. Berezovsky DE, Sitko KR. Pediatric Myasthenia Gravis. *Semin Pediatr Neurol.* 2017;24(2):116–21.
53. Liew WKM, Powell CA, Sloan SR, Shamberger RC, Weldon CB, Darras BT, *et al.* Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. *JAMA Neurol.* 2014;71(5):575–80.